【文章內(nèi)容簡介】 of cardiac pacemakers and antiarrhythmia devices: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2021. Available at I 類適應證 : 竇房結(jié)功能不良的起搏治療 , 包括引起癥狀的頻繁的竇性停搏 ?部分患者的竇性心動過緩是由于必須進行某些治療而又無其他可替代藥物的結(jié)果 Gregoratos G. et al. ACC/AHA/NASPE 2021 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2021. Available at IIa 類適應證 : 竇房結(jié)功能不良的起搏治療 ，心率 40 bpm, 雖有心動過緩的癥狀，但未證實與所發(fā)生的心動過緩有關(guān) ，電生理檢查或激發(fā)試驗證實存在竇房結(jié)功能不良。 Gregoratos G. et al. ACC/AHA/NASPE 2021 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2021. Available at IIb 類適應證 : 竇房結(jié)功能不良的起搏治療 – 清醒狀態(tài)下心率長期 40 bpm, 但癥狀輕微 . Gregoratos G. et al. ACC/AHA/NASPE 2021 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2021. Available at III 類適應證 : 竇房結(jié)功能不良的起搏治療 1. 無癥狀的患者，包括長期應用藥物所致的明顯竇性心動過緩 (HR 40 bpm) 2. 竇房結(jié)功能不良患者有類似心動過緩的癥狀，但證實該癥狀與心動過緩無關(guān) 3. 竇房結(jié)功能不良患者使用非必須應用的藥物治療引起的癥狀性心動過緩 Gregoratos G. et al. ACC/AHA/NASPE 2021 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2021. Available at Section IE: 起搏預防和終止心動過速 Gregoratos G. et al. ACC/AHA/NASPE 2021 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2021. Available at I類： 無 IIa類 : 可被起搏終止、反復發(fā)作的有癥狀 SVT ， 但導管消融和 /或藥物治療無效或產(chǎn)生不可耐受的副作用 I類和 IIa 類適應證 : (自動檢測和起搏終止心動過速 ) Gregoratos G. et al. ACC/AHA/NASPE 2021 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2021. Available at ? 可被起搏終止的反復發(fā)作 SVT或房撲， 起搏作為藥物治療或消融的替代 IIb 類適應證 : 起搏預防和終止心動過速 (自動檢測和起搏終止心動過速 ) Gregoratos G. et al. ACC/AHA/NASPE 2021 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2021. Available at ，無論旁路是否參與心動過速 III 類適應證 : 起搏預防和終止心動過速 (自動檢測和起搏終止心動過速 ) Gregoratos G. et al. ACC/AHA/NASPE 2021 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2021. Available at I類 : VT， 不論是否伴長 QT， 起搏治療證明有效 IIa類 : QT綜合征高?；颊? I 類和 IIa 類適應證 : 起搏預防和終止心動過速 (起搏預防心動過速 ) Gregoratos G. et al. ACC/AHA/NASPE 2021 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2021. Available at 折返的心動過速 、 有癥狀的、藥物難治的陣發(fā)性房顫 IIb 類適應證 : 起搏預防和終止心動過速 (起搏預防心動過速 ) Gregoratos G. et al. ACC/AHA/NASPE 2021 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2021. Available at